Bioatla Inc (BCAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bioatla Inc (BCAB) has a cash flow conversion efficiency ratio of 0.141x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.27 Million) by net assets ($-37.31 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Bioatla Inc for the company's overall valuation and market capitalisation.
Bioatla Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Bioatla Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bioatla Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioatla Inc ranked by their cash flow conversion efficiency. See how well can Bioatla Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZIMI Ltd
AU:ZMM
|
-0.423x |
|
UMT United Mobility Technology AG
XETRA:UMD
|
0.141x |
|
CPD SA
WAR:CPD
|
-0.023x |
|
Future Lifestyle Fashions Limited
NSE:FLFL
|
-0.089x |
|
Whitehawk Ltd
AU:WHK
|
-3.809x |
|
Argent Biopharma Ltd
AU:RGT
|
0.379x |
|
Jadestone Energy Inc
LSE:JSE
|
-0.550x |
|
Elong Power Holding Limited Class A Ordinary Shares
NASDAQ:ELPW
|
0.046x |
Annual Cash Flow Conversion Efficiency for Bioatla Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Bioatla Inc from 2018 to 2025. View today's stock price for Bioatla Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-36.19 Million | $-48.20 Million | 1.332x | +126.41% |
| 2024-12-31 | $14.27 Million | $-71.94 Million | -5.043x | -242.63% |
| 2023-12-31 | $70.67 Million | $-104.02 Million | -1.472x | -193.54% |
| 2022-12-31 | $180.34 Million | $-90.42 Million | -0.501x | -69.90% |
| 2021-12-31 | $210.82 Million | $-62.21 Million | -0.295x | -70.54% |
| 2020-12-31 | $209.97 Million | $-36.33 Million | -0.173x | -200.49% |
| 2019-12-31 | $-56.01 Million | $-9.64 Million | 0.172x | -86.13% |
| 2018-12-31 | $-28.45 Million | $-35.32 Million | 1.242x | -- |
About Bioatla Inc
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); a… Read more